Overhauled AERS II System Will Be Overseen By Bioinformatics Board

A new Bioinformatics Board will oversee FDA's program to develop an advanced Adverse Event Reporting System with the capability to analyze data and assist medical reviewers in spotting safety signals

More from Archive

More from Pink Sheet